|
44 Companies |
|
74 Products |
|
74 Products |
|
52 Mechanisms of Action |
|
4 Trials |
|
352 News |
|
| 12345678» |
- | dilanubicel (DVX101) / Deverra Therapeutics
Phase classification, Enrollment change, Trial termination: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 26, 2018
P1, N=7, Terminated, Sponsor: Nohla Therapeutics, Inc.
Phase classification: P=N/A --> P1 | N=15 --> 7 | Active, not recruiting --> Terminated
- | cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial completion, Enrollment change, Post-transplantation: Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer (clinicaltrials.gov) - Aug 31, 2018
P2, N=142, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase classification: P=N/A --> P1 | N=15 --> 7 | Active, not recruiting --> Terminated Active, not recruiting --> Completed | N=92 --> 142
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Phase classification, Enrollment change, Trial termination: Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia (clinicaltrials.gov) - Aug 23, 2018
P1, N=7, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Completed | N=92 --> 142 Phase classification: P=N/A --> P1 | N=25 --> 7 | Active, not recruiting --> Terminated; Expiration of study supply
- | Trial completion date, Trial termination: Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer (clinicaltrials.gov) - Aug 16, 2018
P=N/A, N=1000, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Phase classification: P=N/A --> P1 | N=25 --> 7 | Active, not recruiting --> Terminated; Expiration of study supply Trial completion date: Dec 2020 --> Feb 2018 | Active, not recruiting --> Terminated; Low accrual
- | Trial completion, Trial completion date, Trial primary completion date: Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer (clinicaltrials.gov) - Jul 19, 2018
P=N/A, N=2545, Completed, Sponsor: Children's Oncology Group
Trial completion date: Dec 2020 --> Feb 2018 | Active, not recruiting --> Terminated; Low accrual Active, not recruiting --> Completed | Trial completion date: Jan 2100 --> Jun 2018 | Trial primary completion date: Jan 2100 --> Jun 2018
- | Trial completion, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Jun 2, 2018
P=N/A, N=80, Completed, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Completed | Trial completion date: Jan 2100 --> Jun 2018 | Trial primary completion date: Jan 2100 --> Jun 2018 Active, not recruiting --> Completed
- | Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 31, 2018
P1, N=10, Terminated, Sponsor: University of Southern California
Active, not recruiting --> Completed N=35 --> 10 | Trial completion date: Mar 2019 --> Aug 2017 | Recruiting --> Terminated | Trial primary completion date: Mar 2018 --> Jul 2017; Insufficient Accrual
- | decitabine / Generic mfg.
Trial completion, Enrollment change: AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 14, 2018
P1, N=13, Completed, Sponsor: Alison Walker
N=35 --> 10 | Trial completion date: Mar 2019 --> Aug 2017 | Recruiting --> Terminated | Trial primary completion date: Mar 2018 --> Jul 2017; Insufficient Accrual Active, not recruiting --> Completed | N=54 --> 13
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Phase classification: Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (clinicaltrials.gov) - Mar 2, 2018
P=N/A, N=0, Approved for marketing, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Completed | N=54 --> 13 Phase classification: P2 --> P=N/A
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Enrollment change, Trial termination, Trial primary completion date: Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (clinicaltrials.gov) - Mar 1, 2018
P2, N=12, Terminated, Sponsor: Wake Forest University Health Sciences
Phase classification: P2 --> P=N/A N=30 --> 12 | Suspended --> Terminated | Trial primary completion date: Aug 2020 --> Jul 2016
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial termination: Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease (clinicaltrials.gov) - Dec 28, 2017
P2, N=24, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
N=30 --> 12 | Suspended --> Terminated | Trial primary completion date: Aug 2020 --> Jul 2016 Completed --> Terminated
- | Enrollment closed: Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer (clinicaltrials.gov) - Dec 13, 2017
P=N/A, N=3000, Active, not recruiting, Sponsor: Children's Oncology Group
Completed --> Terminated Recruiting --> Active, not recruiting
- | Enbrel (etanercept) / Pfizer, Amgen
Clinical: Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant (clinicaltrials.gov) - Sep 29, 2017
P2, N=39, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: Total Marrow Irradiation for Refractory Acute Leukemia (clinicaltrials.gov) - Jul 28, 2017
P1, N=12, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Nov 2016
- ||| Trial completion, Minimal residual disease: MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 1, 2017
P=N/A, N=150, Completed, Sponsor: Center for International Blood and Marrow Transplant Research
Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Nov 2016 Active, not recruiting --> Completed
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Phase classification: Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (clinicaltrials.gov) - May 30, 2017
P2, N=30, Suspended, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Completed Phase classification: P=N/A --> P2
- | fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial completion, Trial initiation date, Trial primary completion date: Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - May 30, 2017
P2, N=71, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Phase classification: P=N/A --> P2 Active, not recruiting --> Completed | Initiation date: Nov 2003 --> Jan 2011 | Trial primary completion date: Dec 2016 --> Jan 2011
- | Trial completion, Trial primary completion date: Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer (clinicaltrials.gov) - May 24, 2017
P2, N=9, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | Initiation date: Nov 2003 --> Jan 2011 | Trial primary completion date: Dec 2016 --> Jan 2011 Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017
- | Trial primary completion date: Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 20, 2017
P1, N=35, Recruiting, Sponsor: University of Southern California
Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017 Trial primary completion date: Mar 2016 --> Mar 2018
- | dapsone / Generic mfg.
Enrollment change: Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone (clinicaltrials.gov) - Apr 17, 2017
P=N/A, N=41, Completed, Sponsor: Vanderbilt University
Trial primary completion date: Mar 2016 --> Mar 2018 N=200 --> 41
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Trial suspension: Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (clinicaltrials.gov) - Apr 14, 2017
P=N/A, N=30, Suspended, Sponsor: Wake Forest University Health Sciences
N=200 --> 41 Recruiting --> Suspended
- | Enrollment closed: Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer (clinicaltrials.gov) - Apr 11, 2017
P2, N=9, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Suspended Recruiting --> Active, not recruiting
- | Trial completion: Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy (clinicaltrials.gov) - Apr 4, 2017
P1, N=5, Completed, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Enrollment closed, Trial primary completion date: Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=1000, Active, not recruiting, Sponsor: Vanderbilt University Medical Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Dec 2014
- | fludarabine IV / Generic mfg.
Trial completion: Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia (clinicaltrials.gov) - Feb 20, 2017
P1, N=2, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Dec 2014 Active, not recruiting --> Completed
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Enrollment change, IO biomarker: Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant (clinicaltrials.gov) - Feb 15, 2017
P1/2, N=7, Terminated, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed N=35 --> 7
- dilanubicel (DVX101) / Deverra Therapeutics
Trial primary completion date: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 15, 2017
P=N/A, N=15, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
N=35 --> 7 Trial primary completion date: Jun 2017 --> Aug 2018
- OXS-1550 / GT Biopharma
Trial completion, Trial initiation date: DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma (clinicaltrials.gov) - Feb 11, 2017
P1, N=25, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Jun 2017 --> Aug 2018 Active, not recruiting --> Completed | Initiation date: Apr 2009 --> Dec 2013
- decitabine / Generic mfg.
Trial primary completion date: AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 23, 2017
P1, N=54, Active, not recruiting, Sponsor: Alison Walker
Active, not recruiting --> Completed | Initiation date: Apr 2009 --> Dec 2013 Trial primary completion date: Dec 2016 --> Aug 2016
- Enrollment closed, Enrollment change, Trial primary completion date: Total Marrow Irradiation for Refractory Acute Leukemia (clinicaltrials.gov) - Dec 8, 2016
P1, N=12, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Dec 2016 --> Aug 2016 Recruiting --> Active, not recruiting | N=20 --> 12 | Trial primary completion date: Sep 2017 --> Feb 2016
- Trial primary completion date: Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer (clinicaltrials.gov) - Nov 9, 2016
P2, N=10, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting | N=20 --> 12 | Trial primary completion date: Sep 2017 --> Feb 2016 Trial primary completion date: Mar 2017 --> Sep 2017
- dilanubicel (DVX101) / Deverra Therapeutics
Enrollment closed: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 2, 2016
P=N/A, N=15, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Mar 2017 --> Sep 2017 Recruiting --> Active, not recruiting
- cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial primary completion date, Post-transplantation: Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer (clinicaltrials.gov) - Oct 18, 2016
P2, N=92, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2015 --> Apr 2017
- dilanubicel (DVX101) / Deverra Therapeutics
Trial primary completion date: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 27, 2016
P=N/A, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jan 2015 --> Apr 2017 Trial primary completion date: Dec 2016 --> Jun 2017
- Trial completion, Trial primary completion date, Minimal residual disease: Comparison of Laboratory Test Results of Minimal-Residual Disease in Samples From Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 12, 2016
P=N/A, N=10, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Dec 2016 --> Jun 2017 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016
- | Biomarker, Trial completion, Trial primary completion date, Heterogeneity: Biomarker Study in Tissue Samples From Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 12, 2016
P=N/A, N=20, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016
- Trial completion, Trial primary completion date: Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 6, 2016
P=N/A, N=96, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016 Withdrawn --> Completed | Trial primary completion date: May 2009 --> Mar 2014
- | ondansetron / Generic mfg.
Trial completion, Metastases: Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment (clinicaltrials.gov) - Jul 4, 2016
P3, N=100, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Withdrawn --> Completed | Trial primary completion date: May 2009 --> Mar 2014 Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer (clinicaltrials.gov) - Jun 29, 2016
P2, N=82, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- dilanubicel (DVX101) / Deverra Therapeutics
Trial completion: Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies (clinicaltrials.gov) - May 23, 2016
P2, N=15, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Biomarker, Trial completion, Trial primary completion date, IO biomarker: Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=20, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- ||| Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Biomarker, Trial completion, Trial primary completion date: Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531 (clinicaltrials.gov) - May 19, 2016
P=N/A, N=1000, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- Trial completion, Trial primary completion date: Cell Samples From Patients With Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=10, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- | Biomarker, Trial completion, Trial primary completion date: Biomarkers in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=20, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- ||| Biomarker, Trial completion, Trial primary completion date: Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=234, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- | Biomarker, Trial completion, Trial primary completion date: Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=32, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- ||| Biomarker, Trial completion, Trial primary completion date: Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=250, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- ||| Trial completion, Trial primary completion date: Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=100, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- Vanflyta (quizartinib) / Daiichi Sankyo
Trial completion, Trial primary completion date: Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=10, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- ||| Biomarker, Trial completion, Trial primary completion date: Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder (clinicaltrials.gov) - May 19, 2016
P=N/A, N=60, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016